Effect of Probiotics on Infantile Colic Symptoms
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Infantile Colic
In brief
The aim of this clinical trial is to assess the impact of B. lactis B94 on participants with infantile colic. It is hypothesized that participants given the probiotic formula will have a significant reduction in their crying duration compared to participants receiving the placebo, after 4 weeks of intervention.
Key facts
- Study ID
- NCT06385054
- Run by
- Lallemand Health Solutions
- People needed
- 70
- Starts
- 2024-08-01
- Expected to finish
- 2027-02-01
- Last updated by the study team
- 2024-08-16
Who can join
Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- I1. Healthy male or female. I2. Age ≤ 8 weeks old. I3. Diagnosis of infantile colic according to the Rome IV criteria. Infants must show cry or fuss behavior for 3 or more hours per day, during 3 or more days in 7 days.
- I4. Exclusively breastfeeding and planning to breastfeed for the duration of the study.
- I5. With a written informed consent signed by the father and mother or legal guardian.
- I6. With parents willing to complete questionnaires, records, and diaries associated to the study and to complete all clinical visits and scheduled telephone calls.
- I7. At least one of the legal representatives is affiliated with a social security scheme.
You may not qualify if…
- E1. Birthweight < 2500 g. E2. Gestational age < 37 weeks. E3. Apgar score at 5 minutes < 7. E4. Partially or fully formula fed infants except for the 4 first days after birth.
- E5. Stunted growth/weight loss (< 100 g/week from birth to last reported). E6. Gastroesophageal reflux disease, short bowel syndrome, chronic intestinal diseases, or gastrointestinal malformations.
- E7. Diagnosed or reported fever and/or infectious diseases, or current systemic infections, or history of congenital infections.
- E8. Genetic diseases and chromosomal abnormalities. E9. Metabolic diseases or pancreatic insufficiency. E10. Immunodeficiency. E11. Neurological diseases. E12. Suspected or confirmed food allergies and intolerances. E13. Mother who consumed antacid medications (proton pump inhibitor and H2 receptor antagonist) within the month before birth and intend to consume any during the trial.
- E14. Use of probiotics, prebiotics, antibiotics, or gastric acid inhibitors by the infant at any time from birth to the moment of screening and during the trial.
- E15. Use of anti-colic medication at any time from birth to the moment of screening.
- E16. Use of probiotics and prebiotics supplements by the mother between the birth of their infant and the moment of screening and intend to consume any during the trial.
- E17. Currently enrolled in another clinical study or having participated in another clinical from birth to the moment of screening.
- E18. Whose legal representatives have psychological or linguistic incapability to sign the informed consent.
- E19. Impossibility to contact the legal representatives in case of emergency.
Where it is running
- Centre Hospitalier de Boulogne-sur-Mer — Boulogne-sur-Mer, France (enrolling)
- Hôpital Saint Vincent de Paul — Lille, France (enrolling)
- Centre Hospitalier du val d'Ariège — Saint-Jean-de-Verges, France (enrolling)
- Cabinet privé Dr Regimbart-Trubuil Christine — Bécon-les-Granits, France
- CHU de NANTES — Nantes, France
- Biofortis, Unité d'investigation Clinique — Paris, France
- Biofortis, Unité d'investigation Clinique — Saint-Herblain, France
- Centre Hospitalier de Montauban — Montauban, France
- CHU Caen Normandie — Caen, France
- CHU Grenoble Alpes — La Tronche, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.